What Liquid Cartilage™ actually requires

For patients researching Liquid Cartilage™ through the Lincolnshire Hip service, the most useful starting question is not 'does it work?' but 'what does it need in order to work?'

Liquid Cartilage™ is the Lincolnshire Hip brand name for ChondroFiller™, a CE-marked Class III collagen scaffold delivered as an outpatient, ultrasound-guided injection into the hip joint — not as open surgery. Once placed at the defect site, the scaffold gels in situ and acts as a matrix for acellular matrix-induced chondrogenesis: the patient's own progenitor cells migrate into the scaffold from the surrounding tissue and support the body's endogenous repair processes at that location.

That mechanism defines the treatment's core requirement. For the scaffold to be contained and for cell migration to occur effectively, the defect must be isolated and focal — a discrete area of Grade III or IV cartilage damage with intact, healthy cartilage borders around it. A joint with widespread damage has no intact margin to work with.

Because the process is regenerative, individual factors such as biological repair capacity are assessed at consultation rather than screened by fixed age or weight cut-offs alone. The sections below explain what happens when those conditions are not met.

When the pattern of wear disqualifies the hip

Widespread cartilage loss across the hip joint surface is the most common reason Liquid Cartilage™ is not offered. The scaffold works by sitting against intact cartilage — the healthy border surrounding the defect acts as both a physical containment wall and the source of the progenitor cells that migrate into the matrix. Where that border is absent, there is nothing to anchor the scaffold or drive repair.

Kellgren-Lawrence Grade IV osteoarthritis — commonly described as bone-on-bone wear — is a clear contraindication. At this stage the articular cartilage is globally thinned or absent across the joint surface; there is no viable margin remaining and no intact tissue from which endogenous repair can be recruited. The same logic applies to large lesions or any pattern in which the surrounding cartilage has been lost or severely compromised, regardless of the patient's age or general health.

End-stage hip disease, where the joint surface is globally affected, falls outside the indication entirely. Given that osteoarthritis affects an estimated 240 million people worldwide, and that many will present with diffuse rather than focal wear by the time they seek specialist opinion, this exclusion is not uncommon. When it applies, the pathway moves directly to alternatives — covered in the sections below.

Medical and structural factors that affect suitability

Beyond the pattern of cartilage damage, two further categories of clinical factor shape suitability: the patient's general health, and the mechanical state of the hip joint itself.

On the health side, active or recent joint infection in the hip must be excluded before any injectable therapy is considered — this is a firm clinical prerequisite, not a matter of individual assessment. Poorly controlled diabetes, immunosuppression, and anticoagulation do not automatically disqualify a patient, but each alters the safety profile or timing. A patient anticoagulated with warfarin, for example, would typically need bridging management before the procedure can safely go ahead — something arranged at consultation rather than treated as a barrier to it. The aim of disclosing these conditions early is to allow proper planning, not to close the door.

Regenerative capacity — the body's ability to mount an effective repair response — is assessed by the clinical team on a case-by-case basis. Where it is judged insufficient, the procedure is not offered regardless of defect geometry. This is an honest limitation: the assessment is qualitative and cannot be reduced to a single test or threshold.

Mechanically, untreated hip impingement, significant malalignment, or instability can perpetuate the very wear the treatment aims to address. Identifying and managing the structural driver first is good clinical logic — correcting it may be a prerequisite before any cartilage preservation approach is viable.

Injectable alternatives when the hip is not focal or contained

Ruling out Liquid Cartilage™ on pattern grounds does not exhaust the injectable options available through the pathway — it redirects to treatments matched to a different clinical picture.

The first point worth clarifying: ChondroFiller® and Liquid Cartilage™ use exactly the same acellular collagen scaffold. The Liquid Cartilage™ name describes an indication — a contained focal defect treated at a single site — rather than a different product. ChondroFiller® injection delivers the identical scaffold under ultrasound guidance as an outpatient procedure for patients with more diffuse wear, and it carries no defect-size limit and no upper age restriction. Rather than targeting one bounded area, it coats the articular surface broadly, making it the natural step when the hip has lost cartilage across a wider area rather than at a single focal point. Active patients in their 60s, 70s, and beyond who wish to preserve the hip joint before considering replacement — or who are not suitable for a more targeted approach — are those this route tends to suit best.

Where synovial inflammation is a primary driver of pain rather than cartilage surface loss, Arthrosamid® works through a distinct mechanism. It is a polyacrylamide hydrogel that integrates into the synovial lining rather than coating the articular surface; it is not a regenerative scaffold and is not interchangeable with ChondroFiller®. Its typical effect is approximately two to three years of symptom relief from a single £3,000 injection. Because the two products act on anatomically separate tissues, they can be administered together at the same outpatient appointment when both are indicated.

PRP injection is a further option within the pathway, particularly for earlier-stage hip osteoarthritis where the clinical goal is inflammatory modulation and biologic tissue support rather than structural surface coverage.

When the hip needs replacing rather than preserving

For a significant number of hip patients, the aim of the pathway is to delay or avoid replacement altogether — published evidence suggests that 62% of people with moderate-to-severe hip osteoarthritis can avoid joint replacement at twelve months through structured exercise, weight management, and education. That figure matters because it sets a realistic baseline: conservative management is not a preamble to treatment but an active strategy running alongside every stage of the pathway. Where it succeeds, replacement never becomes necessary.

Where it does not — and for patients whose hip has reached end-stage osteoarthritis, with preservation no longer clinically viable — replacement is not a failure. It is the right treatment at the right stage.

The Lincolnshire Hip service offers SPAIRE hip replacement, which stands for Save Piriformis And Internus, Repair Externus. It is a posterior surgical approach that keeps the short external rotator tendons at the back of the hip intact rather than detaching them, with the aim of supporting natural joint stability and, for suitable patients, more confident early mobilisation. Professor Paul Lee trained in the SPAIRE approach under Professor Timperley at the Exeter Hip Unit and performs the surgery personally at the five-star Weymouth Street Hospital in London.

Post-operative recovery and unlimited physiotherapy are delivered locally, at the service's Grantham and Sleaford sites, so patients do not need to remain in London to complete their rehabilitation. The package is priced at £17,800 fully inclusive — covering consultation, surgery, overnight stay, and unlimited local physiotherapy — with no supplement charges or undisclosed additions.

Total hip replacement replaces both the femoral head and the acetabulum with prosthetic components. Published data suggest approximately 58% of total hip replacements remain in place at 25 years, a useful reference point when weighing timing, though individual outcomes depend on factors a consultation will address in detail.

How the Lincolnshire Hip pathway finds your right treatment

Clinical assessment is where the pathway described in this article becomes specific to one hip rather than a general framework. At an initial consultation in Sleaford or Grantham, Professor Lee maps the history, imaging, and examination findings against the criteria covered above — pattern of wear, degree of degeneration, mechanical factors, and health status — to identify which stage of the pathway fits that joint. That process is as useful when it rules something out as when it confirms a route in: a patient found unsuitable for Liquid Cartilage™ leaves with a clear reason and a matched alternative, whether that is ChondroFiller® injection for diffuse wear, Arthrosamid® for synovial inflammation, or SPAIRE hip replacement for end-stage disease.

No GP referral is needed to book. Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment, with consultations available locally in Grantham and Sleaford and surgery, where required, at Weymouth Street Hospital in London.